A peptide fragment from the human COX3 protein disrupts association of Mycobacterium tuberculosis virulence proteins ESAT-6 and CFP10, inhibits mycobacterial growth and mounts protective immune response

BMC Infectious Diseases

Anand Ranganathan⁴  Gobardhan Das³  Prashini Moodley³  Maitree Bhattacharyya¹  Sushil Kumar⁴  Prem Prakash⁴  Kuhulika Bhalla⁴  Anamika Ghosh⁴  Arun Kumar²  Dhiraj Kumar Singh²  Sultan Tousif³  Sachin Kumar Samuchiwal⁴ 

[1] Department of Biochemistry, University of Calcutta, 35, Ballygunge Circular Road, Kolkata 700 019, India;Immunology Group, International Centre for Genetic Engineering and Biotechnology, ICGEB, Aruna Asaf Ali Marg, New Delhi 110067, India;School of Laboratory Medicine, College of Health Sciences, University of Kwazulu-Natal, Durban, South Africa;Recombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, ICGEB, Aruna Asaf Ali Marg, New Delhi 110067, India

关键词: Th17;    Th1;    Protein-protein interactions;    CFP10;    ESAT-6;    Human COX3;    Tuberculosis;   

Others  :  1127469
DOI  :  10.1186/1471-2334-14-355

 received in 2014-02-06, accepted in 2014-06-25,  发布年份 2014

【 摘 要 】

Background

Tuberculosis (TB) is one of the most prevalent infectious diseases affecting millions worldwide. The currently available anti-TB drugs and vaccines have proved insufficient to contain this scourge, necessitating an urgent need for identification of novel drug targets and therapeutic strategies. The disruption of crucial protein-protein interactions, especially those that are responsible for virulence in Mycobacterium tuberculosis – for example the ESAT-6:CFP10 complex – are a worthy pursuit in this direction.

Methods

We therefore sought to improvise a method to attenuate M. tuberculosis while retaining the latter’s antigenic properties. We screened peptide libraries for potent ESAT-6 binders capable of dissociating CFP10 from ESAT-6. We assessed the disruption by a peptide named HCL2, of the ESAT-6:CFP10 complex and studied its effects on mycobacterial survival and virulence.

Results

We found that HCL2, derived from the human cytochrome c oxidase subunit 3 (COX3) protein, disrupts ESAT-6:CFP10 complex, binds ESAT-6 potently, disintegrates bacterial cell wall and inhibits extracellular as well as intracellular mycobacterial growth. In addition, an HCL2 expressing M. tuberculosis strain induces both Th1 and Th17 host protective responses.

Conclusions

Disruption of ESAT-6:CFP10 association could, therefore, be an alternate method for attenuating M. tuberculosis, and a possible route towards future vaccine generation.

【 授权许可】

   
2014 Samuchiwal et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Global tuberculosis control: Annual Report on Global Tuberculosis Scenario by World Health Organization. 2011. [http://whqlibdoc.who.int/publications/2011/9789241564380_eng.pdf webcite] Accessed 05 February 2012
• [2]Kaufmann SH: Is the development of a new tuberculosis vaccine possible? Nat Med 2000, 6:955-960.
• [3]Chatterjee S, Dwivedi VP, Singh Y, Siddiqui I, Sharma P, Van Kaer L, Chattopadhyay D, Das G: Early secreted antigen ESAT-6 of Mycobacterium tuberculosis promotes protective T helper 17 cell responses in a toll-like receptor-2-dependent manner. PLoS Pathog 2011, 7:e1002378.
• [4]Chandra Rai R, Dwivedi VP, Chatterjee S, Raghava Prasad DV, Das G: Early secretory antigenic target-6 of Mycobacterium tuberculosis: enigmatic factor in pathogen-host interactions. Microbes Infect 2012, 14:1220-1226.
• [5]Hokey DA, Ginsberg A: The current state of tuberculosis vaccines. Hum Vaccin Immunother 2013, 9:48-47. PMID: 23792698; http://dx.doi.org/10.4161/hv.25427 webcite
• [6]Bonah C: The 'experimental stable' of the BCG vaccine: safety, efficacy, proof, and standards, 1921–1933. Stud Hist Philos Biol Biomed Sci 2005, 36:696-721.
• [7]Zhang Y: The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol 2005, 45:529-564.
• [8]Yew WW, Leung CC: Antituberculosis drugs and hepatotoxicity. Respirology 2006, 11:699-707.
• [9]Alksne LE: Virulence as a target for antimicrobial chemotherapy. Expert Opin Investig Drugs 2002, 11:1149-1159.
• [10]Pym AS, Brodin P, Brosch R, Huerre M, Cole ST: Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol Microbiol 2002, 46:709-712.
• [11]Renshaw PS, Panagiotidou P, Whelan A, Gordon SV, Hewinson RG, Williamson RA, Carr MD: Conclusive evidence that the major T-cell antigens of the Mycobacterium tuberculosis complex ESAT-6 and CFP-10 form a tight, 1:1 complex and characterization of the structural properties of ESAT-6, CFP-10, and the ESAT-6:CFP-10 Complex. J Biol Chem 2002, 277:21598-21603.
• [12]Meher AK, Bal NC, Chary KV, Arora A: Mycobacterium tuberculosis H37Rv ESAT-6–CFP-10 complex formation confers thermodynamic and biochemical stability. FEBS J 2006, 273:1445-1462.
• [13]Lewis KN, Liao R, Guinn KM, Hickey MJ, Smith S, Behr MA, Sherman DR: Deletion of RD1 from Mycobacterium tuberculosis Mimics Bacille Calmette-Guerin Attenuation. J Infect Dis 2003, 187:117-123.
• [14]de Jonge MI, Pehau-Arnaudet G, Fretz MM, Romain F, Bottai D, Brodin P, Honoré N, Marchal G, Jiskoot W, England P, Cole ST, Brosch R: ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity. J Bacteriol 2007, 189:6028-6034.
• [15]Volkman HEV, Clay H, Beery D, Chang JC, Sherman DR, Ramakrishnan L: Tuberculous granuloma formation is enhanced by a mycobacterium virulence determinant. PLoS Biol 2004, 2:e367.
• [16]Tharad M, Samuchiwal SK, Bhalla K, Ghosh A, Kumar K, Kumar S, Ranganathan A: A three-hybrid system to probe in vivo protein-protein interactions: application to the essential proteins of the RD1 complex of M. tuberculosis. PLoS One 2011, 6:e27503.
• [17]Kumar K, Tharad M, Ganapathy S, Ram G, Narayan A, Khan JA, Pratap R, Ghosh A, Samuchiwal SK, Kumar S, Bhalla K, Gupta D, Natarajan K, Singh Y, Ranganathan A: Phenylalanine-rich peptides potently bind ESAT-6, a virulence determinant of Mycobacterium tuberculosis, and concurrently affect the pathogen’s growth. PLoS One 2009, 4:e7615.
• [18]Kumar D, Nath L, Kamal MA, Varshney A, Jain A, Singh S, Rao KV: Genome wide analysis of the host intracellular network that regulates survival of Mycobacterium tuberculosis. Cell 2010, 140:731-743.
• [19]Tousif S, Singh Y, Prasad DV, Sharma P, Van Kaer L, Das G: T cells from programmed death-1 deficient mice respond poorly to Mycobacterium tuberculosis infection. PLoS One 2011, 6:e19864.
• [20]Lamichhane G, Raghunand TR, Morrison NE, Woolwine SC, Tyagi S, Kandavelou K, Bishai WR: Deletion of a Mycobacterium tuberculosis proteasomal ATPase homologue gene produces a slow-growing strain that persists in host tissues. J Infect Dis 2006, 9:1233-1240.
• [21]Wang X, Barnes PF, Dobos-Elder KM, Townsend JC, Chung YT, Shams H, Weis SE, Samten B: ESAT-6 inhibits production of IFN-γ by Mycobacterium tuberculosis-responsive human T cells. J Immunol 2009, 182:3668-3677.
• [22]Guo S, Xue R, Li Y, Wang SM, Ren L, Xu JJ: The CFP10/ESAT-6 complex of Mycobacterium tuberculosis may function as a regulator of macrophage cell death at different stages of tuberculosis infection. Med Hypotheses 2012, 78:389-392.
• [23]Derrick SC, Morris SL: The ESAT-6 protein of Mycobacterium tuberculosis induces apoptosis of macrophages by activating caspase expression. Cell Microbiol 2007, 9:1547-1555.
• [24]Samten B, Wang X, Barnes PF: Mycobacterium tuberculosis ESX-1 system-secreted protein ESAT-6 but not CFP10 inhibits human T-cell immune responses. Tuberculosis 2009, 89:S74-S76.
• [25]Mahairas GG, Sabo JJ, Hickey MJ, Singh DC, Stover CK: Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol 1996, 178:1274-1282.
• [26]Brodin P, Rosenkrands I, Andersen P, Cole ST, Brosch R: ESAT-6 proteins: protective antigens and virulence factors? Trends Microbiol 2004, 12:500-508.
• [27]Ganguly N, Siddiqui I, Sharma P: Role of M. tuberculosis RD-1 region encoded secretory proteins in protective response and virulence. Tuberculosis (Edinb) 2008, 88:510-517.